Clinuvel Pharmaceuticals Ltd
Buy, Hold or Sell?
Let's analyze Clinuvel together
I guess you are interested in Clinuvel Pharmaceuticals Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.
I'm going to help you getting a better view of Clinuvel Pharmaceuticals Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.
Get notifications about Clinuvel Pharmaceuticals Ltd
I send you an email if I find something interesting about Clinuvel Pharmaceuticals Ltd.
1. Quick Overview
1.1. Quick analysis of Clinuvel (30 sec.)
1.2. What can you expect buying and holding a share of Clinuvel? (30 sec.)
How much money do you get?
What is your share worth?
+ What do you gain per year?
2. Detailed Analysis
2.1. Valuation of Clinuvel (5 min.)
2.2. Growth of Clinuvel (5 min.)
2.3. Financial Health of Clinuvel (5 min.)
2.4. Comparing to competitors in the Biotechnology industry (5 min.)
Industry Rankings (Biotechnology)
3. Summary and Key Metrics
3.1. What can you expect buying and holding a share of Clinuvel?
Welcome investor! Clinuvel's management wants to use your money to grow the business. In return you get a share of Clinuvel.
First you should know what it really means to hold a share of Clinuvel. And how you can make/lose money.
Speculation
The Price per Share of Clinuvel is $9.28. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.
If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:
- The fundamentals: the financial health trends of Clinuvel.
- The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
- The book value: what is the market price compared to it's book value.
Investing
If you really want to invest in Clinuvel, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:
- You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.14. Based on the TTM, the Book Value Change Per Share is $0.51 per quarter. Based on the YOY, the Book Value Change Per Share is $0.33 per quarter.
- You may receive quarterly/yearly dividend in the form of additional shares.
- You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.03 per quarter.
How much money are you going to get?
MRQ | TTM | YOY | 5Y | 10Y | ||||||
---|---|---|---|---|---|---|---|---|---|---|
$ | % of Price per Share | $ | % of Price per Share | $ | % of Price per Share | $ | % of Price per Share | $ | % of Price per Share | |
Usd Eps | 0.40 | 4.3% | 0.40 | 4.3% | 0.27 | 2.9% | 0.29 | 3.1% | 0.15 | 1.6% |
Usd Book Value Change Per Share | 0.51 | 5.5% | 0.51 | 5.5% | 0.33 | 3.6% | 0.32 | 3.5% | 0.20 | 2.1% |
Usd Dividend Per Share | 0.03 | 0.3% | 0.03 | 0.3% | 0.02 | 0.2% | 0.02 | 0.2% | 0.01 | 0.1% |
Usd Total Gains Per Share | 0.53 | 5.7% | 0.53 | 5.7% | 0.35 | 3.8% | 0.34 | 3.7% | 0.21 | 2.2% |
Usd Price Per Share | 12.00 | - | 12.00 | - | 9.75 | - | 16.80 | - | 10.44 | - |
Price to Earnings Ratio | 30.22 | - | 30.22 | - | 35.96 | - | 62.96 | - | 30.77 | - |
Price-to-Total Gains Ratio | 22.58 | - | 22.58 | - | 28.00 | - | 56.70 | - | 44.00 | - |
Price to Book Ratio | 5.62 | - | 5.62 | - | 5.98 | - | 15.28 | - | 14.27 | - |
Price-to-Total Gains Ratio | 22.58 | - | 22.58 | - | 28.00 | - | 56.70 | - | 44.00 | - |
When do you get the money?
Usd Investment | |
---|---|
Usd Price Per Share | 9.28 |
Number of shares | 107 |
Gains per Quarter | Trailing 12 Months | 5 Year |
---|---|---|
Usd Dividend Per Share | 0.03 | 0.02 |
Usd Book Value Change Per Share | 0.51 | 0.32 |
Usd Total Gains Per Share | 0.53 | 0.34 |
Gains per Quarter (107 shares) | 56.86 | 36.26 |
Gains per Year (107 shares) | 227.45 | 145.05 |
Years | Return on Investment (TTM) | Return on Investment (5Y) | ||||
---|---|---|---|---|---|---|
Dividend | Book Value gain | Total gains | Dividend | Book Value gain | Total gains | |
Broker costs | - | - | -10 | - | - | -10 |
1 | 11 | 216 | 217 | 7 | 138 | 135 |
2 | 22 | 433 | 444 | 15 | 275 | 280 |
3 | 33 | 649 | 671 | 22 | 413 | 425 |
4 | 44 | 866 | 898 | 30 | 550 | 570 |
5 | 55 | 1082 | 1125 | 37 | 688 | 715 |
6 | 66 | 1299 | 1352 | 45 | 826 | 860 |
7 | 77 | 1515 | 1579 | 52 | 963 | 1005 |
8 | 88 | 1732 | 1806 | 60 | 1101 | 1150 |
9 | 99 | 1948 | 2033 | 67 | 1238 | 1295 |
10 | 110 | 2165 | 2260 | 75 | 1376 | 1440 |
How sure are you?
Based on the past periods, how sure are you to get value out of your investment.
Linear %
Trailing 12 Months | 3Y | 5 Year | 10 Year | ALLTIME | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% | % | % | % | % | ||||||||||||||||
Earnings Per Share | 1.0 | 0.0 | 0.0 | 100.0% | 3.0 | 0.0 | 0.0 | 100.0% | 5.0 | 0.0 | 0.0 | 100.0% | 7.0 | 3.0 | 0.0 | 70.0% | 7.0 | 16.0 | 0.0 | 30.4% |
Book Value Change Per Share | 1.0 | 0.0 | 0.0 | 100.0% | 3.0 | 0.0 | 0.0 | 100.0% | 5.0 | 0.0 | 0.0 | 100.0% | 9.0 | 1.0 | 0.0 | 90.0% | 14.0 | 9.0 | 0.0 | 60.9% |
Dividend per Share | 1.0 | 0.0 | 0.0 | 100.0% | 3.0 | 0.0 | 0.0 | 100.0% | 5.0 | 0.0 | 0.0 | 100.0% | 7.0 | 0.0 | 3.0 | 70.0% | 7.0 | 0.0 | 16.0 | 30.4% |
Total Gains per Share | 1.0 | 0.0 | 0.0 | 100.0% | 3.0 | 0.0 | 0.0 | 100.0% | 5.0 | 0.0 | 0.0 | 100.0% | 9.0 | 1.0 | 0.0 | 90.0% | 14.0 | 9.0 | 0.0 | 60.9% |
3.2. Key Performance Indicators
The key performance indicators of Clinuvel Pharmaceuticals Ltd compared to the Most Recent Quarter (MRQ).
End of day | +/- | Most Recent Quarter | Trailing 12 Months | +/- | Year-Over-Year | +/- | 5 Year | +/- | 10 Year | +/- | |
---|---|---|---|---|---|---|---|---|---|---|---|
Book Value Change Per Share | - | - | 0.506 | 0.506 | 0% | 0.332 | +52% | 0.321 | +57% | 0.195 | +159% |
Book Value Per Share | - | - | 2.136 | 2.136 | 0% | 1.631 | +31% | 1.363 | +57% | 0.828 | +158% |
Current Ratio | - | - | 7.438 | 7.438 | 0% | 10.237 | -27% | 10.620 | -30% | 9.854 | -25% |
Debt To Asset Ratio | - | - | 0.150 | 0.150 | 0% | 0.128 | +18% | 0.110 | +37% | 0.113 | +32% |
Debt To Equity Ratio | - | - | 0.177 | 0.177 | 0% | 0.146 | +21% | 0.124 | +42% | 0.129 | +37% |
Dividend Per Share | - | - | 0.026 | 0.026 | 0% | 0.016 | +60% | 0.017 | +47% | 0.011 | +127% |
Eps | - | - | 0.397 | 0.397 | 0% | 0.271 | +46% | 0.287 | +38% | 0.146 | +173% |
Free Cash Flow Per Share | - | - | -0.013 | -0.013 | 0% | -0.006 | -58% | 0.040 | -133% | 0.014 | -196% |
Free Cash Flow To Equity Per Share | - | - | -0.042 | -0.042 | 0% | -0.025 | -41% | 0.020 | -311% | 0.023 | -283% |
Gross Profit Margin | - | - | 1.000 | 1.000 | 0% | 1.000 | 0% | 0.961 | +4% | 1.003 | 0% |
Intrinsic Value_10Y_max | - | - | 0.702 | - | - | - | - | - | - | - | - |
Intrinsic Value_10Y_min | - | - | -0.165 | - | - | - | - | - | - | - | - |
Intrinsic Value_1Y_max | - | - | 0.047 | - | - | - | - | - | - | - | - |
Intrinsic Value_1Y_min | - | - | -0.012 | - | - | - | - | - | - | - | - |
Intrinsic Value_3Y_max | - | - | 0.159 | - | - | - | - | - | - | - | - |
Intrinsic Value_3Y_min | - | - | -0.040 | - | - | - | - | - | - | - | - |
Intrinsic Value_5Y_max | - | - | 0.292 | - | - | - | - | - | - | - | - |
Intrinsic Value_5Y_min | - | - | -0.072 | - | - | - | - | - | - | - | - |
Market Cap | 464963264.000 | -34% | 621791964.000 | 621791964.000 | 0% | 504820329.000 | +23% | 854843355.604 | -27% | 529592573.665 | +17% |
Net Profit Margin | - | - | 0.391 | 0.391 | 0% | 0.318 | +23% | 0.464 | -16% | -0.333 | +185% |
Operating Margin | - | - | 0.623 | 0.623 | 0% | 0.557 | +12% | 0.547 | +14% | -0.380 | +161% |
Operating Ratio | - | - | 0.437 | 0.437 | 0% | 0.462 | -6% | 0.486 | -10% | 1.397 | -69% |
Pb Ratio | 4.344 | -29% | 5.617 | 5.617 | 0% | 5.979 | -6% | 15.283 | -63% | 14.267 | -61% |
Pe Ratio | 23.367 | -29% | 30.216 | 30.216 | 0% | 35.959 | -16% | 62.960 | -52% | 30.774 | -2% |
Price Per Share | 9.280 | -29% | 12.000 | 12.000 | 0% | 9.750 | +23% | 16.802 | -29% | 10.439 | +15% |
Price To Free Cash Flow Ratio | -695.967 | +23% | -899.958 | -899.958 | 0% | -1728.150 | +92% | -1177.538 | +31% | -1413.541 | +57% |
Price To Total Gains Ratio | 17.462 | -29% | 22.581 | 22.581 | 0% | 28.003 | -19% | 56.697 | -60% | 44.004 | -49% |
Quick Ratio | - | - | 12.237 | 12.237 | 0% | 16.881 | -28% | 16.082 | -24% | 12.362 | -1% |
Return On Assets | - | - | 0.158 | 0.158 | 0% | 0.145 | +9% | 0.205 | -23% | 0.034 | +361% |
Return On Equity | - | - | 0.186 | 0.186 | 0% | 0.166 | +12% | 0.229 | -19% | 0.030 | +521% |
Total Gains Per Share | - | - | 0.531 | 0.531 | 0% | 0.348 | +53% | 0.339 | +57% | 0.206 | +158% |
Usd Book Value | - | - | 110697980.553 | 110697980.553 | 0% | 84425900.513 | +31% | 69899479.170 | +58% | 42300924.450 | +162% |
Usd Book Value Change Per Share | - | - | 0.506 | 0.506 | 0% | 0.332 | +52% | 0.321 | +57% | 0.195 | +159% |
Usd Book Value Per Share | - | - | 2.136 | 2.136 | 0% | 1.631 | +31% | 1.363 | +57% | 0.828 | +158% |
Usd Dividend Per Share | - | - | 0.026 | 0.026 | 0% | 0.016 | +60% | 0.017 | +47% | 0.011 | +127% |
Usd Eps | - | - | 0.397 | 0.397 | 0% | 0.271 | +46% | 0.287 | +38% | 0.146 | +173% |
Usd Free Cash Flow | - | - | -690912.517 | -690912.517 | 0% | -292116.111 | -58% | 2016308.398 | -134% | 691139.116 | -200% |
Usd Free Cash Flow Per Share | - | - | -0.013 | -0.013 | 0% | -0.006 | -58% | 0.040 | -133% | 0.014 | -196% |
Usd Free Cash Flow To Equity Per Share | - | - | -0.042 | -0.042 | 0% | -0.025 | -41% | 0.020 | -311% | 0.023 | -283% |
Usd Market Cap | 464963264.000 | -34% | 621791964.000 | 621791964.000 | 0% | 504820329.000 | +23% | 854843355.604 | -27% | 529592573.665 | +17% |
Usd Price Per Share | 9.280 | -29% | 12.000 | 12.000 | 0% | 9.750 | +23% | 16.802 | -29% | 10.439 | +15% |
Usd Profit | - | - | 20578510.178 | 20578510.178 | 0% | 14038679.866 | +47% | 14926244.101 | +38% | 7551275.640 | +173% |
Usd Revenue | - | - | 52663254.223 | 52663254.223 | 0% | 44191669.141 | +19% | 34377444.076 | +53% | 20787998.483 | +153% |
Usd Total Gains Per Share | - | - | 0.531 | 0.531 | 0% | 0.348 | +53% | 0.339 | +57% | 0.206 | +158% |
EOD | +3 -5 | MRQ | TTM | +0 -0 | YOY | +23 -12 | 5Y | +19 -17 | 10Y | +23 -13 |
3.3 Fundamental Score
Penke's Stock Scanner
Indicator | Condition | Value | ||
---|---|---|---|---|
Price to Earnings Ratio (EOD) | Between | 0-15 | 23.367 | |
Price to Book Ratio (EOD) | Between | 0-1 | 4.344 | |
Net Profit Margin (MRQ) | Greater than | 0 | 0.391 | |
Operating Margin (MRQ) | Greater than | 0 | 0.623 | |
Quick Ratio (MRQ) | Greater than | 1 | 12.237 | |
Current Ratio (MRQ) | Greater than | 1 | 7.438 | |
Debt to Asset Ratio (MRQ) | Less than | 1 | 0.150 | |
Debt to Equity Ratio (MRQ) | Less than | 1 | 0.177 | |
Return on Equity (MRQ) | Greater than | 0.15 | 0.186 | |
Return on Assets (MRQ) | Greater than | 0.05 | 0.158 | |
Total | 8/10 (80.0%) |
3.4 Technical Score
Penke's Symbol Scanner
Indicator | Condition | Value | ||
---|---|---|---|---|
Rsi | Greater than | 50 | 4.050 | |
Ma 20 | Greater than | Ma 50 | 11.351 | |
Ma 50 | Greater than | Ma 100 | 11.158 | |
Ma 100 | Greater than | Ma 200 | 10.463 | |
Open | Greater than | Close | 9.280 | |
Total | 3/5 (60.0%) |
4. In-depth Analysis
4.1 About Clinuvel Pharmaceuticals Ltd
- https://www.clinuvel.com
- Biotechnology
- 0
- 535 Bourke Street, Melbourne, VIC, Australia, 3000
Google Maps Bing Maps
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRΓNUMBRA, a liquid injectable formulation of afamelanotide. The company was founded in 1987 and is headquartered in Melbourne, Australia.
Fundamental data was last updated by Penke on 2024-08-30 23:48:02.
4.2 In-depth Summary
4.2.1. Financial Health Summary
Compared to previous year | Compared to industry | |
---|---|---|
The company is making a huge profit. | ||
Using its assets, the company is efficient in making profit. | ||
Using its investors money, the company is efficient in making profit. |
Compared to previous year | Compared to industry | |
---|---|---|
The company is operating very efficient. | ||
The company is very efficient in keeping operating costs low. |
Compared to previous year | Compared to industry | |
---|---|---|
The company is very able to pay all its short-term debts. | ||
The company is very able to pay all its short-term debts with the most liquid assets. |
Compared to previous year | Compared to industry | |
---|---|---|
The company is very able to pay all its debts by selling its assets. | ||
The company is very able to pay all its debts with equity. |
4.2.2. Valuation Summary
Compared to previous year | Compared to industry | |
---|---|---|
Based on the equity, the company is overpriced. | ||
Based on the earnings, the company is overpriced. | ||
Based on how much money comes from the company's main activities, the company is expensive. |
4.3 Financial Health
4.3.1. Profitability
4.3.1 Profitability
4.3.1.1. Net Profit Margin
- Above 10% is considered healthy but always compareΒ Clinuvel to theΒ Biotechnology industry mean.
- A Net Profit Margin of 39.1%Β means thatΒ $0.39 for each $1Β in revenue is generated as profit.
Let's take a look of the Net Profit Margin trends of Clinuvel Pharmaceuticals Ltd:
Trends
- The YOY is 31.8%. Compared to the TTM, the mid term is trending up. +2
- The 5Y is 46.4%. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is -33.3%. Compared to the 5Y term, the 10Y term is trending up. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 39.1% | TTM | 39.1% | 0.0% | |
TTM | 39.1% | YOY | 31.8% | +7.3% | |
TTM | 39.1% | 5Y | 46.4% | -7.3% | |
5Y | 46.4% | 10Y | -33.3% | +79.7% |
Compared to industry (Biotechnology)
Let compare the company's Net Profit Margin with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -128.6%. trending up. +2
- The TTM average (mean) in the Biotechnology industry is -208.9%. trending up. +2
4.3.1.2. Return on Assets
- Above 5% is considered healthyΒ but always compareΒ Clinuvel to theΒ Biotechnology industry mean.
- 15.8% Return on Assets means thatΒ Clinuvel generatedΒ $0.16 profit for each $1 in assets.
Let's take a look of the Return on Assets trends of Clinuvel Pharmaceuticals Ltd:
Trends
- The YOY is 14.5%. Compared to the TTM, the mid term is trending up. +2
- The 5Y is 20.5%. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is 3.4%. Compared to the 5Y term, the 10Y term is trending up. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 15.8% | TTM | 15.8% | 0.0% | |
TTM | 15.8% | YOY | 14.5% | +1.3% | |
TTM | 15.8% | 5Y | 20.5% | -4.7% | |
5Y | 20.5% | 10Y | 3.4% | +17.1% |
Compared to industry (Biotechnology)
Let compare the company's Return on Assets with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -11.1%. trending up. +2
- The TTM average (mean) in the Biotechnology industry is -11.7%. trending up. +2
4.3.1.3. Return on Equity
- Above 15%-20% is considered healthy but always compareΒ Clinuvel to theΒ Biotechnology industry mean.
- 18.6% Return on Equity means Clinuvel generated $0.19Β for eachΒ $1 the owners (shareholders) invested.
Let's take a look of the Return on Equity trends of Clinuvel Pharmaceuticals Ltd:
Trends
- The YOY is 16.6%. Compared to the TTM, the mid term is trending up. +2
- The 5Y is 22.9%. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is 3.0%. Compared to the 5Y term, the 10Y term is trending up. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 18.6% | TTM | 18.6% | 0.0% | |
TTM | 18.6% | YOY | 16.6% | +2.0% | |
TTM | 18.6% | 5Y | 22.9% | -4.3% | |
5Y | 22.9% | 10Y | 3.0% | +19.9% |
Compared to industry (Biotechnology)
Let compare the company's Return on Equity with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -13.8%. trending up. +2
- The TTM average (mean) in the Biotechnology industry is -15.9%. trending up. +2
4.3.2. Operating Efficiency of Clinuvel Pharmaceuticals Ltd.
4.3.2. Operating Efficiency
4.3.2.1. Operating Margin
- Measures how much profit Clinuvel makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
- Above 15% is considered healthy but always compareΒ Clinuvel to theΒ Biotechnology industry mean.
- An Operating Margin of 62.3%Β means the company generated $0.62 Β for each $1 in revenue (before taxes).
Let's take a look of the Operating Margin trends of Clinuvel Pharmaceuticals Ltd:
Trends
- The YOY is 55.7%. Compared to the TTM, the mid term is trending up. +2
- The 5Y is 54.7%. Compared to the TTM, the 5Y term is trending up. +2
- The 10Y is -38.0%. Compared to the 5Y term, the 10Y term is trending up. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 62.3% | TTM | 62.3% | 0.0% | |
TTM | 62.3% | YOY | 55.7% | +6.6% | |
TTM | 62.3% | 5Y | 54.7% | +7.5% | |
5Y | 54.7% | 10Y | -38.0% | +92.8% |
Compared to industry (Biotechnology)
Let compare the company's Operating Margin with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -206.3%. trending up. +2
- The TTM average (mean) in the Biotechnology industry is -244.2%. trending up. +2
4.3.2.2. Operating Ratio
- Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
- An Operation Ratio of 0.44 means that the operating costs are $0.44 for each $1 in net sales.
Let's take a look of the Operating Ratio trends of Clinuvel Pharmaceuticals Ltd:
Trends
- The YOY is 0.462. Compared to the TTM, the mid term is trending down. +2
- The 5Y is 0.486. Compared to the TTM, the 5Y term is trending down. +2
- The 10Y is 1.397. Compared to the 5Y term, the 10Y term is trending down. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 0.437 | TTM | 0.437 | 0.000 | |
TTM | 0.437 | YOY | 0.462 | -0.026 | |
TTM | 0.437 | 5Y | 0.486 | -0.049 | |
5Y | 0.486 | 10Y | 1.397 | -0.911 |
Compared to industry (Biotechnology)
Let compare the company's Operating Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 2.631. trending down. +2
- The TTM average (mean) in the Biotechnology industry is 3.198. trending down. +2
4.4.3. Liquidity of Clinuvel Pharmaceuticals Ltd.
4.4.3. Liquidity
4.4.3.1. Current Ratio
- Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
- A Current Ratio of 7.44Β means the company has $7.44 in assets for each $1 in short-term debts.
Let's take a look of the Current Ratio trends of Clinuvel Pharmaceuticals Ltd:
Trends
- The YOY is 10.237. Compared to the TTM, the mid term is trending down. -2
- The 5Y is 10.620. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is 9.854. Compared to the 5Y term, the 10Y term is trending up. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 7.438 | TTM | 7.438 | 0.000 | |
TTM | 7.438 | YOY | 10.237 | -2.800 | |
TTM | 7.438 | 5Y | 10.620 | -3.183 | |
5Y | 10.620 | 10Y | 9.854 | +0.766 |
Compared to industry (Biotechnology)
Let compare the company's Current Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 3.739. trending up. +2
- The TTM average (mean) in the Biotechnology industry is 3.909. trending up. +2
4.4.3.2. Quick Ratio
- Above 1 is considered healthy butΒ always compareΒ Clinuvel to theΒ Biotechnology industry mean.
- A Quick Ratio of 12.24Β means the company can pay off $12.24 for each $1 in debt (using most liquid assets).
Let's take a look of the Quick Ratio trends of Clinuvel Pharmaceuticals Ltd:
Trends
- The YOY is 16.881. Compared to the TTM, the mid term is trending down. -2
- The 5Y is 16.082. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is 12.362. Compared to the 5Y term, the 10Y term is trending up. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 12.237 | TTM | 12.237 | 0.000 | |
TTM | 12.237 | YOY | 16.881 | -4.644 | |
TTM | 12.237 | 5Y | 16.082 | -3.845 | |
5Y | 16.082 | 10Y | 12.362 | +3.720 |
Compared to industry (Biotechnology)
Let compare the company's Quick Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 2.366. trending up. +2
- The TTM average (mean) in the Biotechnology industry is 3.226. trending up. +2
4.5.4. Solvency of Clinuvel Pharmaceuticals Ltd.
4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio
- Below 1 (100%) is considered healthy but always compareΒ Clinuvel to Biotechnology industry mean.
- A Debt to Asset Ratio of 0.15Β means that Clinuvel assets areΒ financed with 15.0% credit (debt) and the remaining percentage (100% - 15.0%)Β is financed by its owners/shareholders.Β
Let's take a look of the Debt to Asset Ratio trends of Clinuvel Pharmaceuticals Ltd:
Trends
- The YOY is 0.128. Compared to the TTM, the mid term is trending up. -2
- The 5Y is 0.110. Compared to the TTM, the 5Y term is trending up. -2
- The 10Y is 0.113. Compared to the 5Y term, the 10Y term is trending down. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 0.150 | TTM | 0.150 | 0.000 | |
TTM | 0.150 | YOY | 0.128 | +0.022 | |
TTM | 0.150 | 5Y | 0.110 | +0.041 | |
5Y | 0.110 | 10Y | 0.113 | -0.004 |
Compared to industry (Biotechnology)
Let compare the company's Debt to Asset Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 0.340. trending down. +2
- The TTM average (mean) in the Biotechnology industry is 0.346. trending down. +2
4.5.4.2. Debt to Equity Ratio
- Below 2 is considered healthy butΒ always compareΒ Clinuvel to theΒ Biotechnology industry mean.
- A Debt to Equity ratio of 17.7% means that company has $0.18 debt for each $1 in shareholders equity.
Let's take a look of the Debt to Equity Ratio trends of Clinuvel Pharmaceuticals Ltd:
Trends
- The YOY is 0.146. Compared to the TTM, the mid term is trending up. -2
- The 5Y is 0.124. Compared to the TTM, the 5Y term is trending up. -2
- The 10Y is 0.129. Compared to the 5Y term, the 10Y term is trending down. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 0.177 | TTM | 0.177 | 0.000 | |
TTM | 0.177 | YOY | 0.146 | +0.030 | |
TTM | 0.177 | 5Y | 0.124 | +0.053 | |
5Y | 0.124 | 10Y | 0.129 | -0.005 |
Compared to industry (Biotechnology)
Let compare the company's Debt to Equity Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 0.394. trending down. +2
- The TTM average (mean) in the Biotechnology industry is 0.446. trending down. +2
4.6. Market Valuation
4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio
- Above 15 is considered overpriced butΒ always compareΒ Clinuvel to theΒ Biotechnology industry mean.
- A PE ratio of 30.22 means the investor is paying $30.22Β for every $1 in earnings.
Let's take a look of the Price to Earnings Ratio trends of Clinuvel Pharmaceuticals Ltd:
Trends
- The YOY is 35.959. Compared to the TTM, the mid term is trending down. +2
- The 5Y is 62.960. Compared to the TTM, the 5Y term is trending down. +2
- The 10Y is 30.774. Compared to the 5Y term, the 10Y term is trending up. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
EOD | 23.367 | MRQ | 30.216 | -6.849 | |
MRQ | 30.216 | TTM | 30.216 | 0.000 | |
TTM | 30.216 | YOY | 35.959 | -5.744 | |
TTM | 30.216 | 5Y | 62.960 | -32.744 | |
5Y | 62.960 | 10Y | 30.774 | +32.186 |
Compared to industry (Biotechnology)
Let compare the company's Price to Earnings Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -2.484. trending up. +2
- The TTM average (mean) in the Biotechnology industry is -2.965. trending up. +2
4.6.2.2. Price To Free Cash Flow Ratio
Let's take a look of the Price To Free Cash Flow Ratio trends of Clinuvel Pharmaceuticals Ltd:
- The EOD is -695.967. Based on how much money comes from the company's main activities, the company is expensive. -2
- The MRQ is -899.958. Based on how much money comes from the company's main activities, the company is expensive. -2
- The TTM is -899.958. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
- The YOY is -1,728.150. Compared to the TTM, the mid term is trending up. -2
- The 5Y is -1,177.538. Compared to the TTM, the 5Y term is trending up. -2
- The 10Y is -1,413.541. Compared to the 5Y term, the 10Y term is trending up. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
EOD | -695.967 | MRQ | -899.958 | +203.990 | |
MRQ | -899.958 | TTM | -899.958 | 0.000 | |
TTM | -899.958 | YOY | -1,728.150 | +828.192 | |
TTM | -899.958 | 5Y | -1,177.538 | +277.580 | |
5Y | -1,177.538 | 10Y | -1,413.541 | +236.003 |
Compared to industry (Biotechnology)
Let compare the company's priceToFreeCashFlowRatio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -3.224. trending down. +2
- The TTM average (mean) in the Biotechnology industry is -3.643. trending down. +2
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio
- At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
- A PB ratio of 5.62 means the investor is paying $5.62Β for each $1 in book value.
Let's take a look of the Price to Book Ratio trends of Clinuvel Pharmaceuticals Ltd:
Trends
- The YOY is 5.979. Compared to the TTM, the mid term is trending down. +2
- The 5Y is 15.283. Compared to the TTM, the 5Y term is trending down. +2
- The 10Y is 14.267. Compared to the 5Y term, the 10Y term is trending up. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
EOD | 4.344 | MRQ | 5.617 | -1.273 | |
MRQ | 5.617 | TTM | 5.617 | 0.000 | |
TTM | 5.617 | YOY | 5.979 | -0.362 | |
TTM | 5.617 | 5Y | 15.283 | -9.666 | |
5Y | 15.283 | 10Y | 14.267 | +1.016 |
Compared to industry (Biotechnology)
Let compare the company's Price to Book Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 1.902. trending up. -2
- The TTM average (mean) in the Biotechnology industry is 2.234. trending up. -2
4.6.2. Total Gains per Share
6. Financial Statements
6.1. Latest Balance Sheet
Balance Sheet of 2023-06-30. Currency in AUD. All numbers in thousands.
Summary
As reported | |
---|---|
Total Liabilities | 29,082 |
Total Stockholder Equity | + 164,631 |
Total Assets | = 193,714 |
Assets
Total Current Assets
Long-term Assets
Property Plant Equipment | 2,851 |
Goodwill | 185 |
Intangible Assets | 185 |
Other Assets | 1,060 |
Long-term Assets (as reported) | 4,096 |
---|---|
Long-term Assets (calculated) | 4,281 |
+/- | 185 |
Liabilities & Shareholders' Equity
Total Current Liabilities
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt | 699 |
Other Liabilities | 2,889 |
Long-term Liabilities (as reported) | 3,588 |
---|---|
Long-term Liabilities (calculated) | 3,588 |
+/- | 0 |
Total Stockholder Equity
Common Stock | 151,849 |
Retained Earnings | -9,774 |
Other Stockholders Equity | 22,556 |
Total Stockholder Equity (as reported) | 164,631 |
---|---|
Total Stockholder Equity (calculated) | 164,631 |
+/- | 0 |
Other
6.2. Balance Sheets Structured
Currency in AUD. All numbers in thousands.
Trend | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 | 2018-06-30 | 2017-06-30 | 2016-06-30 | 2015-06-30 | 2014-06-30 | 2013-06-30 | 2012-06-30 | 2011-06-30 | 2010-06-30 | 2009-06-30 | 2008-06-30 | 2007-06-30 | 2006-06-30 | 2005-06-30 | 2004-06-30 | 2003-06-30 | 2002-06-30 | 2001-06-30 | 2000-06-30 | |||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
> Total Assets |
| 193,714 | 143,950 | 108,568 | 81,542 | 62,345 | 42,905 | 28,607 | 20,138 | 13,644 | 17,154 | 15,815 | 15,995 | 20,165 | 29,507 | 41,614 | 54,971 | 67,825 | 17,071 | 10,056 | 10,247 | 8,066 | 10,520 | 13,769 | 15,441 | ||||||||||||||||||||||||
> Total Current Assets |
| 189,618 | 140,583 | 102,848 | 75,156 | 61,153 | 42,269 | 28,470 | 19,974 | 13,575 | 17,039 | 15,668 | 15,807 | 19,932 | 29,158 | 40,594 | 53,120 | 65,317 | 13,917 | 5,246 | 5,682 | 2,748 | 4,483 | 7,028 | 7,995 | ||||||||||||||||||||||||
Cash And Cash Equivalents |
| 156,814 | 121,509 | 82,691 | 66,747 | 54,269 | 36,198 | 23,752 | 13,845 | 10,572 | 14,626 | 12,569 | 12,719 | 12,178 | 19,415 | 21,711 | 25,752 | 33,842 | 8,606 | 4,763 | 5,480 | 2,612 | 4,414 | 6,981 | 7,927 | ||||||||||||||||||||||||
Short-term Investments |
| 132,946 | 94,100 | 45,550 | 41,095 | 28,525 | 0 | 0 | 0 | 0 | 0 | 0 | 454 | 5,321 | 7,588 | 16,043 | 25,048 | 28,512 | 2,024 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||
Net Receivables |
| 22,215 | 16,202 | 16,089 | 6,613 | 4,156 | 5,090 | 3,239 | 4,824 | 1,960 | 1,585 | 1,743 | 1,007 | 974 | 363 | 212 | 616 | 241 | 233 | 137 | 78 | 31 | 30 | 35 | 57 | ||||||||||||||||||||||||
Other Current Assets |
| 1,070 | 1,039 | 882 | 509 | 592 | 339 | 237 | 223 | 70 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 40 | 47 | 0 | 106 | 39 | 13 | 0 | ||||||||||||||||||||||||
> Long-term Assets |
| 4,096 | 3,367 | 5,719 | 6,386 | 1,193 | 636 | 137 | 165 | 69 | 114 | 146 | 188 | 233 | 349 | 1,020 | 1,851 | 2,508 | 3,154 | 4,810 | 4,565 | 5,318 | 6,037 | 6,741 | 7,446 | ||||||||||||||||||||||||
Property Plant Equipment |
| 2,851 | 2,700 | 2,603 | 2,389 | 707 | 169 | 137 | 165 | 69 | 114 | 146 | 179 | 215 | 322 | 357 | 431 | 332 | 222 | 249 | 120 | 147 | 141 | 116 | 94 | ||||||||||||||||||||||||
Goodwill |
| 185 | 185 | 185 | 185 | 185 | 185 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||
Intangible Assets |
| 185 | 185 | 185 | 185 | 185 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 18 | 28 | 663 | 1,420 | 2,176 | 2,932 | 4,561 | 4,445 | 5,171 | 5,896 | 6,624 | 7,352 | ||||||||||||||||||||||||
Other Assets |
| 1,060 | 482 | 2,931 | 3,812 | 301 | 282 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||
> Total Liabilities |
| 29,082 | 18,390 | 9,830 | 7,873 | 5,166 | 3,489 | 3,163 | 2,304 | 2,439 | 1,726 | 1,976 | 2,358 | 3,757 | 3,081 | 4,563 | 3,156 | 2,433 | 3,082 | 2,601 | 1,392 | 535 | 211 | 318 | 124 | ||||||||||||||||||||||||
> Total Current Liabilities |
| 25,495 | 13,732 | 8,707 | 6,660 | 4,960 | 3,471 | 3,148 | 2,288 | 2,435 | 1,718 | 1,946 | 2,339 | 3,717 | 3,040 | 4,544 | 3,147 | 2,428 | 3,067 | 2,577 | 1,370 | 535 | 211 | 318 | 124 | ||||||||||||||||||||||||
Short-term Debt |
| 301 | 315 | 258 | 212 | 261 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||
Accounts payable |
| 2,792 | 259 | 2,324 | 1,430 | 1,500 | 429 | 579 | 231 | 261 | 178 | 184 | 839 | 1,697 | 569 | 2,056 | 734 | 1,597 | 2,535 | 2,346 | 1,180 | 466 | 157 | 291 | 115 | ||||||||||||||||||||||||
Other Current Liabilities |
| 22,402 | 13,158 | 6,125 | 5,018 | 3,199 | 3,042 | 2,568 | 2,057 | 2,175 | 1,540 | 1,762 | 1,500 | 2,020 | 2,471 | 2,488 | 2,413 | 831 | 532 | 231 | 191 | 70 | 54 | 27 | 9 | ||||||||||||||||||||||||
> Long-term Liabilities |
| 3,588 | 4,658 | 1,123 | 1,213 | 205 | 18 | 15 | 15 | 3 | 8 | 29 | 19 | 40 | 41 | 19 | 9 | 5 | 15 | 24 | 22 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||
Other Liabilities |
| 2,889 | 3,717 | 78 | 106 | 34 | 18 | 15 | 15 | 3 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||
> Total Stockholder Equity |
| 164,631 | 125,559 | 98,737 | 73,669 | 57,180 | 39,416 | 25,386 | 17,796 | 11,205 | 15,428 | 13,839 | 13,637 | 16,408 | 26,426 | 37,051 | 51,815 | 65,392 | 13,989 | 7,454 | 8,855 | 7,531 | 10,310 | 13,451 | 15,317 | ||||||||||||||||||||||||
Common Stock |
| 151,849 | 151,849 | 151,849 | 151,849 | 151,314 | 148,615 | 148,413 | 146,765 | 138,465 | 133,567 | 126,710 | 119,323 | 113,339 | 113,228 | 113,221 | 113,222 | 112,813 | 52,726 | 35,123 | 25,494 | 16,580 | 15,382 | 15,382 | 15,692 | ||||||||||||||||||||||||
Retained Earnings | -9,774 | -38,402 | -58,130 | -80,037 | -95,487 | -112,681 | -125,847 | -133,063 | -129,958 | -119,577 | -114,122 | -107,507 | -100,145 | -88,971 | -78,337 | -63,172 | -49,066 | -39,890 | -27,668 | -16,639 | -9,050 | -5,073 | -1,932 | -374 | |||||||||||||||||||||||||
Capital Surplus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||
Other Stockholders Equity |
| 22,556 | 12,112 | 5,018 | 1,850 | 1,352 | 3,482 | 2,820 | 4,095 | 2,698 | 1,438 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
6.3. Balance Sheets
Currency in AUD. All numbers in thousands.
6.4. Cash Flows
Currency in AUD. All numbers in thousands.
6.5. Income Statements
Currency in AUD. All numbers in thousands.
6.6. Latest Income Statement
Income Statement (annual), 2023-06-30. Currency in AUD. All numbers in thousands.
Gross Profit (+$) | ||
---|---|---|
totalRevenue | 78,321 | |
Cost of Revenue | -8,790 | |
Gross Profit | 69,532 | 69,532 |
Operating Income (+$) | ||
Gross Profit | 69,532 | |
Operating Expense | -25,429 | |
Operating Income | 48,771 | 44,102 |
Operating Expense (+$) | ||
Research Development | 1,268 | |
Selling General Administrative | 22,567 | |
Selling And Marketing Expenses | - | |
Operating Expense | 25,429 | 23,835 |
Net Interest Income (+$) | ||
Interest Income | 3,906 | |
Interest Expense | -3,193 | |
Other Finance Cost | -0 | |
Net Interest Income | 713 | |
Pretax Income (+$) | ||
Operating Income | 48,771 | |
Net Interest Income | 713 | |
Other Non-Operating Income Expenses | - | |
Income Before Tax (EBT) | 45,579 | 48,008 EBIT - interestExpense = 45,579 45,579 33,797 |
Interest Expense | 3,193 | |
Earnings Before Interest and Taxes (EBIT) | 48,771 | 48,771 |
Earnings Before Interest and Taxes (EBITDA) | 49,561 | |
After tax Income (+$) | ||
Income Before Tax | 45,579 | |
Tax Provision | -14,974 | |
Net Income From Continuing Ops | 30,605 | 30,605 |
Net Income | 30,605 | |
Net Income Applicable To Common Shares | 30,605 | |
Non-recurring Events | ||
Discontinued Operations | - | |
Extraordinary Items | - | |
Effect of Accounting Charges | - | |
Other Items | - | |
Non Recurring | - | |
Other Operating Expenses | 34,219 | |
Total Other Income/Expenses Net | 763 | -713 |
Technical Analysis of Clinuvel
The psychology behind the price
Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.
General trend
First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Clinuvel. The general trend of Clinuvel is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Clinuvel's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.
Indicator phases
Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:
Indicator zone transitions | Bullish trend (0.0%) | Bearish trend (0.0%) | |
---|---|---|---|
Overbought to neutral | Bullish pullback | = | Bearish reversal |
Upper to lower neutral | Bullish correction | = | Bearish continuation |
Nuetral to oversold | Oversold | = | Oversold |
Oversold to neutral | Bullish reversal | = | Bearish correction |
Lower to upper neutral | Bullish continuation | = | Bearish pullback |
Nuetral to overbought | Overbought | = | Overbought |
1. Price Targets
1.1 Support & Resistance
Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.
SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.
Score
Let's take a look at the Support & Resistance of Clinuvel Pharmaceuticals Ltd.
The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).
- Between support/resistance: The price is trading between support and resistance lines.
The bullish price targets are: 9.51 < 9.51 < 9.51.
The bearish price targets are: 8.78 > 8.78 > 8.78.
Tweet this